Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.

@article{Buzdar2003AdvancesIE,
  title={Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.},
  author={Aman U. Buzdar},
  journal={The oncologist},
  year={2003},
  volume={8 4},
  pages={335-41}
}
For the past 25 years, the estrogen antagonist tamoxifen has been the hormonal treatment of choice for postmenopausal patients with hormone-sensitive metastatic and early breast cancer (EBC). However, tamoxifen is associated with certain tolerability and safety concerns. In addition, the hormonal options after progression are limited, and thus, alternative endocrine treatments have been developed. This review provides a synopsis of the newer alternatives in endocrine therapy of breast cancer… CONTINUE READING